Bauer takes role of president at Chemwerth

Formerly with Sandoz

Jeffrey Bauer has taken over as president of ChemWerth, a US supplier of active pharmaceutical ingredients for generic medicines.

Prior to joining ChemWerth, Bauer was vice president of business development and licensing at Sandoz, a position that he held for five years beginning in 2005. At Sandoz, Bauer managed the US generic product portfolio as well as active pharmaceutical ingredient (API) sourcing and procurement.

Before Sandoz, Bauer worked at Eon Labs, a generic pharmaceutical company acquired by Sandoz in 2005. In total, Bauer has 18 years’ experience in the pharmaceutical and medical device industries.

ChemWerth was founded in 1982 to supply the emerging generic pharmaceutical industry with sources of high quality APIs. The firm represents numerous US FDA approved facilities in China, as well as a growing number of cGMP manufacturing facilities in the US, Europe and India.

You may also like

Manufacturing

Rezon Bio launches as European biologics CDMO with mirrored sites in Poland

New CDMO combines cost efficiency, digital innovation and EMA/FDA-audited facilities in Gdańsk and Warsaw to accelerate biologics development and commercialisation
Manufacturing

Baxter earns first Gold Resiliency Badge from HIRC across IV, nutrition and premix drug categories

The company is the first manufacturer to receive the Healthcare Industry Resilience Collaborative’s gold badge for IV solutions, nutrition solutions and premix drugs, recognising its leadership in building a transparent, reliable and disruption-ready healthcare supply chain
Analysis

From West to East: building biotech bridges across APAC and the Middle East

Amid rising geopolitical uncertainty, US biotech companies are looking beyond tariffs and trade tensions to expand into Asia-Pacific and the Middle East
Distribution

Er-Kim partners with Sentynl Therapeutics to expand access to ultra-rare disease treatments Nulibry and Zokinvy

The collaboration aims to provide timely access to these EMA- and FDA-approved therapies for patients with life-threatening ultra-rare conditions, including molybdenum cofactor deficiency Type A and Hutchinson-Gilford Progeria Syndrome
Ingredients

CPHI 2025: BENEO to present galenIQ as the granulation binder of choice

At this year’s CPHI Europe in Frankfurt (28–30 October), BENEO will showcase the latest advancements in granulation with its pharmaceutical-grade isomalt excipient: galenIQ
Manufacturing

Gerresheimer and Portal Instruments team up to commercialise PRIME Nexus reusable autoinjector

Gerresheimer and Portal Instruments are joining forces to develop and manufacture the PRIME Nexus syringe-based, reusable, connected autoinjector platform, offering pharmaceutical companies an end-to-end solution for delivering chronic disease therapies
Pharmaceutical

Biognosys expands multiomic capabilities with biocrates metabolomics and lipidomics for drug discovery

The expansion provides biopharma and clinical researchers with a scalable, high-precision multiomics platform to support drug discovery and biomarker research delivering deeper insights into complex biological systems
Subscribe now